Celiac Disease: HLA-DQ2/DQ8 Genetics, Intestinal Damage & the Path to Diagnosis

The Genetic Foundation: HLA-DQ2 and HLA-DQ8

Celiac disease is one of the most thoroughly understood autoimmune conditions in gastroenterology, and its genetic architecture is unusually well-defined. Unlike most autoimmune diseases where heritability is diffuse, celiac disease centers on a specific region of chromosome 6p21 — the major histocompatibility complex (MHC) class II genes encoding human leukocyte antigen (HLA) proteins.

Approximately 90–95% of celiac patients carry HLA-DQ2.5, encoded by the alleles HLA-DQA1*05 and HLA-DQB1*02. Another 5–10% carry HLA-DQ8, encoded by HLA-DQA1*03 and HLA-DQB1*03:02. A minority carry alternative DQ2 heterodimers such as DQ2.2 (DQA1*02:01/DQB1*02:02), which confer partial susceptibility.

Why HLA Genotype Alone Doesn't Cause Celiac Disease

Here is a critical nuance that even many clinicians underemphasize: 30–40% of the general Western population carries HLA-DQ2 or HLA-DQ8, yet only 1% develop celiac disease. This means HLA genotype is necessary but not sufficient. Multiple environmental and genetic co-factors must converge:

• Timing of gluten introduction in infancy (though current evidence has challenged the protective role of breastfeeding timing)
• Gut microbiome composition — dysbiosis may increase intestinal permeability and antigen presentation
• Gastrointestinal infections — rotavirus, adenovirus, and reovirus have been proposed as triggers
• Non-HLA genetic loci — GWAS studies have identified ~57 additional susceptibility loci (including IL-21, PTPN2, RGS1, and SH2B3) that modify disease penetrance
• Gluten load — higher dietary gluten correlates with earlier onset in genetically susceptible individuals

HLA genotyping is most useful as a rule-out test: the absence of both DQ2 and DQ8 makes celiac disease extremely unlikely (negative predictive value exceeding 99%), making it a powerful tool for excluding the diagnosis in first-degree relatives or in ambiguous serological situations.

Inheritance Patterns and Family Risk

Celiac disease shows clear familial clustering. First-degree relatives of confirmed patients have a 10–15% lifetime risk of developing the disease, far above the population rate. Concordance in identical twins reaches 75–85%, confirming that genetic factors dominate but environmental triggers determine expression. Siblings who share both HLA haplotypes with an affected individual face the highest relative risk.

The Immune Cascade: From Gliadin to tTG2 Autoimmunity

Understanding the immunopathology of celiac disease requires tracking gluten from the moment it enters the gastrointestinal tract to the point at which the immune system attacks the intestinal lining. This cascade is elegant, intricate, and now well-mapped.

Step 1 — Gluten, Gliadin, and Partial Digestion

Gluten is a storage protein composite found in wheat (and related grains: barley, rye). It consists of two protein families: glutenins and gliadins. Gliadins — specifically α-, β-, γ-, and ω-gliadins — are the primary immunogenic triggers in celiac disease.

Human digestive enzymes cannot completely hydrolyze gluten. The proline-rich repetitive sequences in gliadin resist breakdown by gastric, pancreatic, and brush-border proteases, yielding large peptide fragments (notably the 33-mer α-gliadin peptide) that accumulate in the intestinal lumen and cross the epithelial barrier.

Step 2 — Transglutaminase 2 (tTG2) and Deamidation

Once gliadin peptides reach the lamina propria — either via paracellular (leaky tight junctions) or transcellular routes — they encounter tissue transglutaminase 2 (tTG2), the dominant autoantigen in celiac disease. tTG2 is an extracellular enzyme that catalyzes the deamidation of specific glutamine residues in gliadin peptides, converting them to glutamate.

This deamidation increases the negative charge of peptide fragments, dramatically improving their binding affinity to HLA-DQ2 and HLA-DQ8 molecules on antigen-presenting cells (APCs). Deamidated gliadin peptides are presented to CD4+ T helper cells in the context of HLA-DQ2/DQ8, initiating the adaptive immune response.

Step 3 — T-Cell Activation and the Innate-Adaptive Interface

Activated CD4+ T cells in the lamina propria produce pro-inflammatory cytokines — primarily interferon-γ (IFN-γ) and interleukin-21 (IL-21) — which amplify the inflammatory response. Simultaneously, gliadin activates innate immune pathways: it directly stimulates epithelial cells to upregulate IL-15, which activates intraepithelial lymphocytes (IELs) bearing natural killer cell receptors (NKG2D).

These activated IELs become cytotoxic to enterocytes, driving the structural damage that defines celiac disease. The interplay between innate IL-15 signaling and adaptive CD4+ T-cell responses creates a self-reinforcing loop that perpetuates intestinal injury as long as gluten exposure continues.

Step 4 — B-Cell Activation and Autoantibody Production

CD4+ T cells provide help to B cells, triggering the production of antibodies against tTG2 itself. This is the autoimmune component: the immune system begins attacking a self-protein. Anti-tTG2 IgA antibodies (tTGA IgA) and anti-endomysial antibodies (EMA IgA) — which target tTG2 in the endomysium of smooth muscle — are the cornerstone serological markers used in clinical diagnosis.

These antibodies are not merely diagnostic bystanders; emerging evidence suggests they may contribute directly to intestinal permeability and vascular pathology, though tTG2 on enterocyte surfaces remains the primary target of immunological injury.

Villous Atrophy: The Marsh Classification System

The structural consequence of ongoing gluten-driven inflammation is progressive destruction of the small intestinal mucosa, particularly in the duodenum and proximal jejunum. This damage is quantified using the Marsh-Oberhuber classification, the international standard for histological grading of celiac disease severity.

Marsh 0 — Normal Mucosa

Marsh 0 represents a completely normal small intestinal biopsy: normal villous architecture, no crypt hyperplasia, and fewer than 25 intraepithelial lymphocytes (IELs) per 100 surface epithelial cells. A Marsh 0 biopsy in a patient consuming gluten makes celiac disease very unlikely.

Marsh 1 — Increased Intraepithelial Lymphocytes

The earliest detectable change: IEL count exceeds 25 per 100 enterocytes, with preserved villous architecture and no crypt changes. Marsh 1 is not specific to celiac disease — it can be seen in Helicobacter pylori infection, NSAID use, common variable immunodeficiency, tropical sprue, and Crohn's disease. Positive serology and HLA typing are essential to attribute Marsh 1 changes to celiac disease.

Marsh 2 — Crypt Hyperplasia

Marsh 2 adds crypt elongation and hyperplasia to increased IELs, still with relatively preserved villi. Crypts proliferate in response to accelerated enterocyte turnover driven by cytotoxic IEL activity. This represents an early adaptive response attempting to compensate for epithelial loss.

Marsh 3 — Villous Atrophy (3a, 3b, 3c)

Marsh 3 represents the full-spectrum celiac lesion — villous atrophy combined with crypt hyperplasia and elevated IELs:

• Marsh 3a: Partial villous atrophy — villi are shortened and blunted but still discernible
• Marsh 3b: Subtotal villous atrophy — most villi absent; mucosa appears flat to near-flat
• Marsh 3c: Total villous atrophy — complete absence of villi; flat mucosa throughout sampled tissue

The degree of villous atrophy correlates with malabsorptive severity. Marsh 3c lesions are associated with the most pronounced deficiencies in iron, folate, calcium, vitamin D, zinc, and fat-soluble vitamins. Diagnosis of celiac disease typically requires at least a Marsh 2 lesion in the context of positive serology and clinical symptoms.

The Importance of Adequate Biopsy Sampling

Celiac disease affects the duodenum in a patchy distribution, particularly in early or mild cases. Current guidelines (ACG, BSG, European Society for Paediatric Gastroenterology) recommend taking at least 4 biopsies from the second and third portion of the duodenum plus at least 1 from the duodenal bulb (D1). Bulbar involvement is common in celiac disease and can be the only site of pathology in some patients.

Diagnosis: Serology, Endoscopy, and When to Use Genetics

Accurate celiac disease diagnosis requires integrating clinical presentation, serological testing, histological findings, and — in selected cases — genetic testing. No single test is sufficient; the diagnostic algorithm must be followed systematically, and critically, patients must be consuming gluten at the time of testing for results to be valid.

Serological Testing

tTGA IgA (anti-tissue transglutaminase IgA) is the recommended first-line serological test. It offers sensitivity of 90–98% and specificity of 95–99% in patients with Marsh 3 lesions. However, sensitivity drops significantly in patients with milder histological changes (Marsh 1–2) or partial villous atrophy.

Total serum IgA must be measured simultaneously, as selective IgA deficiency (prevalence ~2–3% in celiac patients vs. 0.3% in general population) causes false-negative tTGA IgA results. If IgA deficiency is confirmed, switch to tTGA IgG or deamidated gliadin peptide (DGP) IgG antibodies.

EMA IgA (anti-endomysial antibody) has near-perfect specificity (~99%) but is more expensive, operator-dependent (indirect immunofluorescence method), and less sensitive than tTGA IgA. It is useful as a confirmatory test in ambiguous cases.

Deamidated gliadin peptide (DGP) antibodies (IgA and IgG) offer slightly lower sensitivity than tTGA IgA in adults but may be particularly useful in young children under 2 years (where tTGA IgA can be less reliable) and in IgA-deficient patients.

Endoscopy and Biopsy

Upper endoscopy with duodenal biopsy remains the gold standard for celiac disease diagnosis in most adult patients. Endoscopic features suggestive of celiac disease include villous atrophy patterns visible under white-light endoscopy: scalloping or loss of duodenal folds, mosaic mucosal pattern, and visible fissures. However, these macroscopic signs have limited sensitivity; biopsy is always required.

In patients with strongly positive serology (tTGA IgA >10× upper limit of normal) and characteristic symptoms, some European guidelines (ESPGHAN 2020) permit a biopsy-sparing diagnosis in children. This remains controversial in adult practice, where biopsy confirmation is still considered standard of care in most international guidelines.

HLA Genotyping

HLA-DQ2/DQ8 testing is most valuable in three clinical scenarios:

1. Ruling out celiac disease in first-degree relatives who are already on a gluten-free diet (avoiding the need for a gluten challenge)
2. Resolving diagnostic uncertainty in patients with positive serology but non-diagnostic biopsy (Marsh 0–1)
3. Evaluating patients with refractory symptoms where the original diagnosis is in question

Management: The Strict Gluten-Free Diet and Nutritional Recovery

The only proven, effective treatment for celiac disease is a strict, lifelong, completely gluten-free diet (GFD). No pharmacological intervention has yet received regulatory approval as a substitute or adjunct for GFD, though several are in late-stage clinical trials. The goal of treatment is threefold: symptom resolution, normalization of serology, and histological healing.

What "Gluten-Free" Actually Means

Per FDA regulations (and mirrored by EU standards), a food labeled "gluten-free" must contain fewer than 20 parts per million (ppm) of gluten. This threshold was chosen because clinical evidence suggests most celiac patients can tolerate levels below 10–20 ppm without mucosal damage, though individual sensitivity varies.

In practice, this means eliminating all products containing wheat (including spelt, kamut, farro, durum, semolina, einkorn), barley (including malt and malt vinegar), rye, and triticale. Oats are inherently gluten-free but are frequently cross-contaminated during processing; only certified gluten-free oats should be consumed, and some celiac patients react to avenin (the oat prolamin) even without contamination.

Cross-Contamination: The Hidden Threat

The majority of adherent celiac patients who fail to achieve mucosal healing are unknowingly consuming gluten through cross-contamination, not deliberate dietary infractions. Sources include:

• Shared toasters, colanders, wooden cutting boards, and cast-iron pans that have absorbed gluten
• Deep fryers where gluten-containing foods have been cooked
• Bulk bins, shared spice jars, and condiment containers
• Restaurant cross-contact during food preparation (dedicated gluten-free kitchen required)
• Medications and supplements containing wheat starch as filler
• Communion wafers, lipstick, and adhesive on envelopes (minimal risk but relevant for highly sensitive individuals)

Timeline of Recovery on a Gluten-Free Diet

Serological normalization (tTGA IgA returning to normal range) typically occurs within 6–12 months on a strict GFD. Histological healing lags behind and is often incomplete even after 2 years: studies show complete villous recovery in only 34% of patients at 2 years and 66–70% at 5 years. Adults — particularly those diagnosed later in life — take longer to achieve mucosal healing than children.

Follow-up endoscopy at 18–24 months is recommended in adults to confirm histological response, particularly in those with persistent symptoms or ongoing positive serology.

Nutritional Deficiencies to Address at Diagnosis

Villous atrophy impairs absorption across the full length of the small intestine. At diagnosis, screen for and address:

• Iron: Most common deficiency; often the presenting feature (microcytic anemia)
• Folate (vitamin B9): Absorbed in the proximal jejunum; deficiency causes macrocytic anemia and neural tube risk
• Vitamin B12: Terminal ileum absorption usually preserved, but deficiency possible in severe disease
• Calcium and vitamin D: Critical for bone density; metabolic bone disease (osteopenia, osteoporosis) is common in newly diagnosed celiac patients
• Zinc: Deficiency contributes to dermatitis, impaired wound healing, and growth retardation in children
• Magnesium: Exacerbated by diarrhea; important for neuromuscular function
• Fat-soluble vitamins (A, E, K): Malabsorbed in moderate-to-severe disease

Refractory Celiac Disease (RCD)

Refractory celiac disease (RCD) is defined as persistent or recurrent malabsorptive symptoms and intestinal damage (Marsh ≥2) despite more than 12 months of confirmed strict adherence to a GFD, after exclusion of other causes (including inadvertent gluten exposure). RCD affects approximately 0.3–0.5% of celiac patients.

RCD is classified into two subtypes based on intraepithelial lymphocyte (IEL) phenotype:

• Type I RCD: IELs have a normal surface phenotype (CD3+, CD8+). Responds to nutritional support, corticosteroids (budesonide), and immunosuppressants (azathioprine). Generally favorable prognosis.
• Type II RCD: IELs have an aberrant phenotype — they lack surface CD3 and CD8 but retain intracytoplasmic CD3. This represents a clonal T-cell expansion that is considered a low-grade lymphoproliferative disorder and carries a 5-year risk of enteropathy-associated T-cell lymphoma (EATL) of approximately 50%. Management requires specialist centers and may involve cladribine, autologous stem cell transplantation, or clinical trials.

Before diagnosing RCD, meticulous dietary review by an experienced dietitian is mandatory — the most common cause of "refractory" celiac disease is continued inadvertent gluten exposure, not true treatment resistance.